RESEARCH OF BIOPHARMACEUTICAL CLUSTERS DEVELOPMENT IN EU COUNTRIES

R Sahaidak-Nikitiuk,S Barnatovych,N Demchenko

doi:10.32702/2307-2105-2020.11.2

R Sahaidak-Nikitiuk, S Barnatovych + Show 1 more

Open Access

https://doi.org/10.32702/2307-2105-2020.11.2

Copy DOI

Abstract

The article analyzes the current state of clustering development in European countries. It has been determined that clusters correspond to the modern approach in economics and are one of the options for the development of high-tech industries. The branch direction of clustering of the EU countries is investigated: electronic technologies and communication, informatics, biotechnologies and bioresources, pharmaceuticals and cosmetics, public health services, agro-production and food production, oil and gas complex and chemistry, mechanical engineering, electronics, communications and transport, power, construction and development, light industry, forest complex. European countries are analyzed by the number of registered biopharmaceutical clusters, their features and examples of clusters in relation to the studied countries. The countries under consideration include Austria, Belgium, Great Britain, Denmark, Estonia, Spain, Italy, Germany, the Netherlands, Hungary, Finland, France, Switzerland. The rank of the European country in the FT Europe-500 rating according to the total market clustering of biopharmaceutical clusters is studied. The specialization of biopharmaceutical clusters Munich, Berlin, Graz, Utrecht, Lelystad, Frankfurt, Mailand, Ghent, Vienna Biocenter, Berkshire, Oresund, Bio-valley has been studied. The definition of "biopharmaceutical cluster" and the purpose of its creation are proposed. The main distinctive features of the cluster approach in pharmacy and biotechnology are formed, the main of which is the possibility of developing innovative drugs with their subsequent production. The advantages of clustering are investigated. That is, the unification of subjects of production, distribution and sale of medicines, science and education, based on the mechanisms of public-private partnership. The goals of creating a biopharmaceutical cluster are determined. The interaction of the participants of the biopharmaceutical cluster in economic, organizational, managerial, social, legal, technical-technological, innovative, informational and ecological directions is determined. The effects of the functioning of the biopharmaceutical cluster for end users, cluster members and the regional economy are formed.

Highlights

The rank of the European country in the FT Europe-500 rating according to the total market clustering of biopharmaceutical clusters is studied
It should be noted that according to the European Commission [11], the first place in terms of investment in research and development in the world is pharmaceuticals and biotechnology (18.9% of global investment in research and development), which are an example of high-tech clusters and actively developing in Europe
Developed national health care system High level of biopharmaceutical research Opportunity for the development of international networks of innovation clusters in the Baltic Sea region The development of the tourism and hospitality industry as a priority of the country's economic policy contributes to the development of the supporting biopharmaceutical industry Significant state support for biotechnology Creation of bioregions

Summary

Introduction

RESEARCH OF BIOPHARMACEUTICAL CLUSTERS DEVELOPMENT IN EU COUNTRIES The EU countries that are leading in the development of clustering in the field of medicine include Denmark, the Netherlands, France, Germany, Italy, Switzerland and Sweden (Table 1) [10].

Objectives

Results

Conclusion